ArticleInternational journal of molecular sciences2022
MIF1 and MIF2 Myostatin Peptide Inhibitors as Potent Muscle Mass Regulators.
Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 22 citations in OpenAlex.
- Myostatin-dependent detrusor remodelling mediates contractility impairment in diabetic rats' bladder - a maximal elastance analysis.The Journal of physiology · 2026Article
- Emerging therapeutic strategies in muscular dystrophy: an updated review on pathogenesis and treatment advances.Molecular biology reports · 2026Review
- Skeletal Muscle Aging: Enhancing Skeletal Muscle Integrity and Function as a Potential Pharmacological Approach.Pharmaceuticals (Basel, Switzerland) · 2025Review
- The Effects of Laxogenin and 5-Alpha-hydroxy-laxogenin on Myotube Formation and Maturation During Cultured Meat Production.International journal of molecular sciences · 2025Article
- Biological insights and therapeutic potential of Glycyrrhiza uralensis and its bioactive compounds: an updated review.Archives of pharmacal research · 2024Review
- Effect ofHeliyon · 2024Article
- Current situation and publication trends of skeletal muscle related research: A bibliometric analysis.Heliyon · 2024Article
- Circulating Myokines as Novel Biomarkers for Cardiovascular Diseases.Reviews in cardiovascular medicine · 2024Review
- Therapeutic applications of ginseng for skeletal muscle-related disorder management.Journal of ginseng research · 2024Review
- Therapeutic Applications of Ginseng Natural Compounds for Health Management.International journal of molecular sciences · 2023Review
- The roles of growth factors and hormones in the regulation of muscle satellite cells for cultured meat production.Journal of animal science and technology · 2023Review
- Skeletal Muscle Regeneration in Cardiotoxin-Induced Muscle Injury Models.International journal of molecular sciences · 2022Review
- Dipeptidyl peptidase-4 inhibitory potentials ofFrontiers in molecular biosciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
The use of peptides as drugs has progressed over time and continues to evolve as treatment paradigms change and new drugs are developed. Myostatin (MSTN) inhibition therapy has shown great promise for the treatment of muscle wasting diseases. Here, we report the MSTN-derived novel peptides MIF1 (10-mer) and MIF2 (10-mer) not only enhance myogenesis by inhibiting MSTN and inducing myogenic-related markers but also reduce adipogenic proliferation and differentiation by suppressing the expression of adipogenic markers. MIF1 and MIF2 were designed based on in silico interaction studies between MSTN and its receptor, activin type IIB receptor (ACVRIIB), and fibromodulin (FMOD). Of the different modifications of MIF1 and MIF2 examined,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.